

WHAT IS CLAIMED IS:

1. A method of modulating the trafficking or activation of a leukocyte in an animal, said method comprising contacting myeloid lineage cells in said animal with a therapeutic amount of:
 - a) an agonist of a mammalian OX2 protein; or
 - b) an antagonist of a mammalian OX2 protein.
2. The method of Claim 1, wherein said:
 - a) mammalian OX2 protein is a primate protein;
 - b) antagonist is an antibody which binds to said mammalian OX2; or
 - c) said cells are monocyte/macrophage lineage cells.
3. The method of Claim 2, wherein said myeloid lineage cells include a monocyte, macrophage, microglial, or dendritic cell.
4. The method of Claim 1, wherein said animal exhibits signs or symptoms of an inflammatory, infective, leukoproliferative, neurodegenerative, or post-traumatic condition.
5. The method of Claim 4, wherein said sign or symptom is in neural tissue; lymphoid tissue; myeloid tissue; pancreas; gastrointestinal tissue; thyroid tissue; muscle tissue; or skin or collagenous tissue.
6. The method of Claim 1, wherein said modulating is inhibiting function of said leukocyte cell.
7. The method of Claim 6, wherein said administering is said agonist.

8. The method of Claim 7, wherein said agonist is said mammalian OX2.

9. The method of Claim 7, wherein said animal is experiencing signs or symptoms of autoimmunity; an inflammatory condition; an infection; tissue specific autoimmunity; degenerative autoimmunity; rheumatoid arthritis; atherosclerosis; multiple sclerosis; vasculitides; delayed hypersensitivities; skin grafting; a transplant; spinal injury; stroke; neurodegeneration; or ischemia.

10. The method of Claim 7, wherein said administering is in combination with:

- a) an anti-inflammatory cytokine agonist or antagonist;
- b) an analgesic;
- c) an anti-inflammatory agent; or
- d) a steroid.

11. The method of Claim 1, wherein said modulating is enhancing function of said leukocyte cell.

12. The method of Claim 11, wherein said administering is said antagonist.

13. The method of Claim 12, wherein said antagonist is:

- a) an antibody which binds to said mammalian OX2; or
- b) a mutein of said mammalian OX2 which competes with said mammalian OX2 in binding to an OX2 receptor, but does not substantially signal.

14. The method of Claim 12, wherein said animal experiences signs or symptoms of wound healing or clot formation.

15. The method of Claim 12, wherein said administering is in combination with:

- a) an angiogenic factor;
- 5 b) a growth factor, including FGF or PDGF;
- c) an antibiotic; or
- d) a clotting factor.

10 16. A method of modulating the activation of a leukocyte in a tissue, said method comprising contacting myeloid lineage cells in said tissue with:

- a) an agonist of a mammalian OX2 protein; or
- b) an antagonist of a mammalian OX2 protein.

15 17. The method of Claim 16, wherein said modulating is inhibiting said leukocyte cell, and said contacting is with said agonist.

20 18. The method of Claim 17, wherein said administering is in combination with:

- a) an anti-inflammatory cytokine agonist or antagonist;
- b) an analgesic;
- c) an anti-inflammatory agent; or
- 25 d) a steroid.

19. The method of Claim 16, wherein said modulating is enhancing, and said contacting is with said antagonist.

30 20. The method of Claim 19, wherein said administering is in combination with:

- a) an angiogenic factor;
- b) a growth factor, including FGF or PDGF;
- c) an antibiotic; or
- 35 d) a clotting factor.

SEQUENCE SUBMISSION

SEQ ID NO: 1 is primate, e.g., human, OX2 sequence.

SEQ ID NO: 2 is rodent, e.g., mouse, OX2 sequence.

5 SEQ ID NO: 3 is rodent, e.g., rat, OX2 sequence.

<110> Schering Corporation

10 <120> Novel Uses of Mammalian OX2 Protein and Related Reagents

<130> DX0936K

<140>

<141>

15 <160> 3

<170> PatentIn Ver. 2.0

$\langle 210 \rangle$ 1

<211> 274

<212> PRT

20 <213> primate.

<400> 1

Val Ile Arg Met Pro Phe Ser His Leu Ser Thr Tyr Ser Leu Val Trp
1 5 10 15

25 Val Met Ala Ala Val Val Leu Cys Thr Ala Gln Val Gln Val Val Thr

Gln Asp Glu Arg Glu Gln Leu Tyr Thr Thr Ala Ser Leu Lys Cys Ser
35 40 45

30 50 55 60 65 70 75 80 85 90 95 100 105 110 115 120 125 130 135 140 145 150 155 160 165 170 175 180 185 190 195 200 205 210 215 220 225 230 235 240 245 250 255 260 265 270 275 280 285 290 295 300 305 310 315 320 325 330 335 340 345 350 355 360 365 370 375 380 385 390 395 400 405 410 415 420 425 430 435 440 445 450 455 460 465 470 475 480 485 490 495 500 505 510 515 520 525 530 535 540 545 550 555 560 565 570 575 580 585 590 595 600 605 610 615 620 625 630 635 640 645 650 655 660 665 670 675 680 685 690 695 700 705 710 715 720 725 730 735 740 745 750 755 760 765 770 775 780 785 790 795 800 805 810 815 820 825 830 835 840 845 850 855 860 865 870 875 880 885 890 895 900 905 910 915 920 925 930 935 940 945 950 955 960 965 970 975 980 985 990 995 1000

Ala Val Ser Pro Glu Asn Met Val Thr Phe Ser Glu Asn His Gly Val
65 70 75 80

Val Ile Gln Pro Ala Tyr Lys Asp Lys Ile Asn Ile Thr Gln Leu Gly

35 Leu Gln Asn Ser Thr Ile Thr Phe Trp Asn Ile Thr Leu Glu Asp Glu
 100 105 110

Gly Cys Tyr Met Cys Leu Phe Asn Thr Phe Gly Phe Gly Lys Ile Ser

40 Gly Thr Ala Cys Leu Thr Val Tyr Val Gln Pro Ile Val Ser Leu His

Tyr Lys Phe Ser Glu Asp His Leu Asn Ile Thr Cys Ser Ala Thr Ala

143				150				155				160			
Arg	Pro	Ala	Pro	Met	Val	Phe	Trp	Lys	Val	Pro	Arg	Ser	Gly	Ile	Glu
				165					170					175	

45 Asn Ser Thr Val Thr Leu Ser His Pro Asn Gly Thr Thr Ser Val Thr

Ser Ile Leu His Ile Lys Asp Pro Lys Asn Gln Val Gly Lys Glu Val

50 Ile Cys Gln Val Leu His Leu Gly Thr Val Thr Asp Phe Lys Gln Thr

210	215	220
Val Asn Lys Gly Tyr Trp	Phe Ser Val Pro Leu	Leu Leu Ser Ile Val

225 230 235 240
Ser Leu Val Ile Leu Leu Val Leu Ile Ser Ile Leu Leu Tyr Trp Lys

55 Arg His Arg Asn Gln Asp Arg Gly Glu Leu Ser Gln Gly Val Gln Lys

Met Thr

<210> 2
 <211> 278
 <212> PRT
 <213> rodent

5

<400> 2

Met Ala Ser Leu Val Phe Arg Arg Pro Phe Cys His Leu Ser Thr Tyr
 1 5 10 15
 Ser Leu Ile Trp Gly Met Ala Ala Val Ala Leu Ser Thr Ala Gln Val
 20 25 30
 Glu Val Val Thr Gln Asp Glu Arg Lys Ala Leu His Thr Thr Ala Ser
 35 40 45
 Leu Arg Cys Ser Leu Lys Thr Ser Gln Glu Pro Leu Ile Val Thr Trp
 50 55 60
 Gln Lys Lys Lys Ala Val Ser Pro Glu Asn Met Val Thr Tyr Ser Lys
 65 70 75 80
 Thr His Gly Val Val Ile Gln Pro Ala Tyr Lys Asp Arg Ile Asn Val
 85 90 95
 Thr Glu Leu Gly Leu Trp Asn Ser Ser Ile Thr Phe Trp Asn Thr Thr
 100 105 110
 Leu Glu Asp Glu Gly Cys Tyr Met Cys Leu Phe Asn Thr Phe Gly Ser
 115 120 125
 Gln Lys Val Ser Gly Thr Ala Cys Leu Thr Leu Tyr Val Gln Pro Ile
 130 135 140
 Val His Leu His Tyr Asn Tyr Phe Glu Asp His Leu Asn Ile Thr Cys
 145 150 155 160
 Ser Ala Thr Ala Arg Pro Ala Pro Ala Ile Ser Trp Lys Gly Thr Gly
 165 170 175
 Thr Gly Ile Glu Asn Ser Thr Glu Ser His Phe His Ser Asn Gly Thr
 180 185 190
 Thr Ser Val Thr Ser Ile Leu Arg Val Lys Asp Pro Lys Thr Gln Val
 195 200 205
 Gly Lys Glu Val Ile Cys Gln Val Leu Tyr Leu Gly Asn Val Ile Asp
 210 215 220
 Tyr Lys Gln Ser Leu Asp Lys Gly Phe Trp Phe Ser Val Pro Leu Leu
 225 230 235 240
 Leu Ser Ile Val Ser Leu Val Ile Leu Leu Val Leu Ile Ser Ile Leu
 245 250 255
 Leu Tyr Trp Lys Arg His Arg Asn Gln Glu Arg Gly Glu Ser Ser Gln
 260 265 270
 Gly Met Gln Arg Met Lys
 275

<210> 3
 <211> 278
 <212> PRT
 <213> rodent

45

<400> 3

Met Gly Ser Pro Val Phe Arg Arg Pro Phe Cys His Leu Ser Thr Tyr
 1 5 10 15
 Ser Leu Leu Trp Ala Ile Ala Ala Val Ala Leu Ser Thr Ala Gln Val
 20 25 30
 Glu Val Val Thr Gln Asp Glu Arg Lys Leu Leu His Thr Thr Ala Ser
 35 40 45
 Leu Arg Cys Ser Leu Lys Thr Thr Gln Glu Pro Leu Ile Val Thr Trp
 50 55 60
 Gln Lys Lys Lys Ala Val Gly Pro Glu Asn Met Val Thr Tyr Ser Lys
 65 70 75 80

